Atossa Genetics Subsidiary Develops New Pharmacogenetic Test
The National Reference Laboratory for Breast Health, an Atossa Genetics subsidiary, has developed a new expanded pharmacogenetic test using Luminex’s xTAG technology.
The test features a genetic analysis of eight additional genes with the goal of enabling better treatment for certain addictions and clinical conditions such as depression, anxiety and other behavioral health problems, the Seattle, Wash., company said Thursday.
The pharmacogenetic test has not received FDA clearance.
Atossa Genetics offers laboratory services, medical devices and therapeutics for breast health treatment.
Austin, Texas-based Luminex develops tests and assays for clinicians and researchers. — Jason Scott